Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed)
ID: 354716Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings" (Funding Opportunity Number PAR-24-234) aimed at advancing research on Alzheimer’s disease-related dementias (ADRD). This initiative encourages researchers to utilize in-cell structural biology methodologies to investigate the molecular and cellular mechanisms of ADRD, focusing on high-resolution characterization of protein structures in their native environments. The program offers up to $3 million annually for five years, with a maximum of $500,000 in direct costs per project per year. Applications must be submitted electronically through Grants.gov by October 4, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services (HHS), specifically the National Institutes of Health (NIH), has announced a new funding opportunity titled "Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings" (Funding Opportunity Number PAR-24-234). This initiative aims to support research leveraging in-cell structural biology methodologies to explore the molecular and cellular mechanisms underlying Alzheimer’s disease-related dementias (ADRD). Researchers are encouraged to focus on high-resolution determination of ADRD-linked protein structures in native settings and further develop research tools to characterize structural findings. The program will provide up to $3 million annually for five years, with a cap of $500,000 direct costs per project per year. Eligible applicants include various educational institutions, nonprofits, and governmental organizations, while applications must be submitted electronically through Grants.gov by the specified deadlines. This funding aligns with the NIH's overarching goals to improve understanding of ADRD and enhance diagnostic tools and treatment strategies. Compliance with application guidelines and early submissions are emphasized to account for potential errors. Overall, this funding opportunity aims to significantly advance mechanistic understandings of ADRD through innovative structural studies.
    Similar Opportunities
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing research on Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the Small Business Innovation Research (SBIR) program. This initiative invites U.S. small businesses to submit applications for innovative research projects that could lead to new therapies, diagnostic technologies, or prevention strategies for AD/ADRD. The funding reflects a significant federal commitment to addressing the challenges posed by these conditions, with a total of $20 million anticipated for approximately 40 awards in 2023, providing up to $500,000 for Phase I and $2.5 million for Phase II projects. Interested applicants can find more details and application requirements at the provided link and should note that the application deadline is September 5, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" aimed at developing a diverse and interdisciplinary workforce for translational research in this critical health area. The initiative invites eligible institutions to create training programs for predoctoral and postdoctoral researchers, focusing on enhancing skills in data science, disease biology, and drug discovery, while not permitting independent clinical trials. With an anticipated budget of approximately $2.7 million annually for 3-5 awards over fiscal years 2025-2027, applications are due by September 25, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.